Dr. Paul J Turek (born July 8, 1960, Manchester, Connecticut) is an American physician and surgeon, men's reproductive health specialist, and businessman.

[1] Turek is a recent recipient of a National Institutes of Health (NIH) grant for research designed to help infertile men become fathers using stem cells.

[6] He is now Director of The Turek Clinics, medical centers in California that specialize exclusively in men's reproductive health care.

Turek has designed and led in numerous key research programs, as well as inventing several procedures, that have had significant impact on the science of men's reproductive health.

FNA Mapping is a non-invasive office procedure that can be performed in a standardized, template fashion to identify men who qualify for, and assist in the planning of, sperm retrieval for IVF-ICSI.

[13] In addition, FNA Mapping has been used to determine the effectiveness of mapping in patients after sterilizing chemotherapy,[14] the ability to find and diagnose small testis tumors,[15] and the ability of mapping to precisely define subsets of infertile men for more accurate phenotyping for molecular biology and genetic studies.,[16][17] In a series of papers, Turek and his team made a significant advancement in the diagnosis of ejaculatory duct obstruction (EDO) as a cause of male infertility by studying and investigating the approach and limitations of current treatments for this condition.,[18][19] This led to a prospective, comparative study of currently used techniques to diagnosis EDO[20] followed by the invention and publication of a dynamic, physiologically relevant test, termed ejaculatory duct manometry, to definitively diagnose this surgical condition.

"[23] Subsequently, his team evolved the Hypoosmotic Swelling Test into a therapeutic tool that harmlessly and physiologically "pokes" a non-moving sperm to determine whether it is alive and therefore able to be used for ICSI.

Turek has published over a dozen papers on improved patient outcomes and decision making from over 800 patients that have entered the program since inception.,[26][27] The debate about the use of embryonic stem cells for research has been loud, acrimonious, and highly politicized with the result that embryonic stem cells were effectively banned for research uses in the United States.

[32] He has examined the toxic effect of medications such as the antioxidant selenium[33] and the anti-inflammatory drug class called biological response modifiers on male fertility.